A Phase I/IIa Study of BMS-986205 Administered in Combination with Nivolumab (BMS-935558 anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

Brief description of study

If you have been diagnosed with advanced(metastatic (spread to another area of the body) and/or unresectable (cannot be removed from the body)) malignant tumors, including melanoma and non-small cell lung cancer, you may qualify to participate in a study evaluating the safety, tolerability, and toxicity levels of BMS-986205 (an inhibitor of the indoleamine 2,3- dioxygenase1) supplied as a single therapy and in combination with Nivolumab (a PD-1 agonist). The main goal of this phase I/IIa is to also investigate the anti-tumor activity of BMS-986205 administered in combination with Nivolumab in various cohorts. In addition, we would like to study blood samples to understand how BMS-986205 is in the blood over time, which is known as pharmacokinetic (PK) testing.

Clinical Study Identifier: s17-00278
ClinicalTrials.gov Identifier: NCT02658890

If you are registered as a volunteer, please login to the dashboard to send referrals.